Enter, Medimix International’s cloud-based platform, LiveTracker™. The real-time drug performance monitoring solution helps pharmaceutical firms to get a better understanding of the effectiveness of their drugs by observing and reporting on a patient journey, physicians’ preference on a particular drug, awareness of the medicine in the market, and other key aspects. Henry Gazay, CEO of Medimix International, says, “Whether you launch innovative drugs, revolutionary medical devices, or leverage the latest advancements in biotechnology, our mission is to provide evidence-based strategic insights to help you come up with the most effective decisions to develop a more efficacious and cost-efficient drug.”
Medimix International: Offering Real-Time Insights on Drug Performance
Using this single source of information that is updated on a monthly basis, pharma companies seamlessly compare the usage and efficiency of their drugs across multiple regions
Today, several pharmaceuticals, diagnostics, and medical device organisations in the oncology and hematology sectors have benefitted immensely by utilizing the accurate and reliable RWE provided by LiveTracker™ on treatment outcomes, patient profiles, and market structure.
These capabilities of LiveTracker™ have earned Medimix International a warm pat from various pharmaceutical and drug development companies. To further expand LiveTracker’s competency across other therapeutic fields, Medimix International has recently joined hands with the Pharmaceutical Product Development (PPD) group’s business unit Evidera, a leading provider of evidence-based solutions. “This acquisition will help us better support our existing clients and expand our customer base with extended resources and expanded geographic footprint,” mentions Gazay.
At the same time, Medimix International is also developing new solutions for other stakeholders in the pharma sector. “Our aim is to bridge the gap between real-world data used for commercial and research purposes and offer a wide range of innovative solutions that push the pharmaceutical industry forward,” wraps up Gazay.